Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Soros Fund Management LLC

Soros Fund Management LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 33.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 200,000 shares of the company’s stock after buying an additional 50,000 shares during the period. Soros Fund Management LLC owned about 0.20% of Neurocrine Biosciences worth $27,300,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in NBIX. Caprock Group LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $236,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company’s stock valued at $104,089,000 after buying an additional 15,266 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at $3,236,000. Oakworth Capital Inc. acquired a new position in shares of Neurocrine Biosciences in the 4th quarter valued at $379,000. Finally, Avantax Advisory Services Inc. boosted its holdings in shares of Neurocrine Biosciences by 11.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company’s stock valued at $395,000 after buying an additional 297 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Down 0.3 %

Shares of Neurocrine Biosciences stock opened at $106.46 on Tuesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The firm has a market cap of $10.53 billion, a PE ratio of 32.36, a P/E/G ratio of 0.77 and a beta of 0.33. The business’s fifty day moving average is $107.00 and its two-hundred day moving average is $122.16.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock repurchase plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NBIX shares. Evercore ISI lowered their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a “hold” rating and a $138.00 price target for the company. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Finally, JPMorgan Chase & Co. increased their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.90.

Insider Buying and Selling

In related news, Director Kevin Charles Gorman sold 5,844 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total value of $681,936.36. Following the transaction, the director now directly owns 521,618 shares of the company’s stock, valued at approximately $60,867,604.42. This trade represents a 1.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 623 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the transaction, the insider now directly owns 3,442 shares in the company, valued at $513,856.18. This trade represents a 15.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,801 shares of company stock valued at $2,834,677. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.